MX2021009378A - Derivados de pirazolopirimidina como inhibidor de cinasa. - Google Patents

Derivados de pirazolopirimidina como inhibidor de cinasa.

Info

Publication number
MX2021009378A
MX2021009378A MX2021009378A MX2021009378A MX2021009378A MX 2021009378 A MX2021009378 A MX 2021009378A MX 2021009378 A MX2021009378 A MX 2021009378A MX 2021009378 A MX2021009378 A MX 2021009378A MX 2021009378 A MX2021009378 A MX 2021009378A
Authority
MX
Mexico
Prior art keywords
kinase inhibitor
pyrazolopyrimidine derivatives
present
pyrazolopyrimidine
derivatives
Prior art date
Application number
MX2021009378A
Other languages
English (en)
Inventor
In Woo Kim
Sun Ah Jun
Jun Hee Lee
Ji Duck Kim
Mi Ryeong Han
Jakyung Yoo
Yun Ju Oh
Nam Youn Kim
Joon Seok Park
Original Assignee
Daewoong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daewoong Pharmaceutical Co Ltd filed Critical Daewoong Pharmaceutical Co Ltd
Publication of MX2021009378A publication Critical patent/MX2021009378A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

La presente invención se refiere a un derivado de pirazolopirimidina, o a una sal farmacéuticamente aceptable del mismo. El compuesto de acuerdo con la presente invención puede usarse de manera útil para la prevención o el tratamiento de enfermedades que están asociadas con acciones inhibidoras de cinasas.
MX2021009378A 2016-06-30 2017-06-30 Derivados de pirazolopirimidina como inhibidor de cinasa. MX2021009378A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160083050 2016-06-30
PCT/KR2017/006980 WO2018004306A1 (en) 2016-06-30 2017-06-30 Pyrazolopyrimidine derivatives as kinase inhibitor

Publications (1)

Publication Number Publication Date
MX2021009378A true MX2021009378A (es) 2022-06-29

Family

ID=60785389

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021009378A MX2021009378A (es) 2016-06-30 2017-06-30 Derivados de pirazolopirimidina como inhibidor de cinasa.
MX2018016287A MX2018016287A (es) 2016-06-30 2017-06-30 Derivados de pirazolopirimidina como inhibidor de cinasa.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2018016287A MX2018016287A (es) 2016-06-30 2017-06-30 Derivados de pirazolopirimidina como inhibidor de cinasa.

Country Status (22)

Country Link
US (1) US10961247B2 (es)
EP (2) EP3950691A1 (es)
JP (2) JP2019519579A (es)
KR (1) KR102329162B1 (es)
CN (2) CN113135920A (es)
AU (1) AU2017287762C1 (es)
BR (1) BR112018074621B1 (es)
CA (1) CA3025636C (es)
CL (1) CL2018003511A1 (es)
CO (1) CO2018013293A2 (es)
DO (1) DOP2018000275A (es)
EC (1) ECSP18093777A (es)
IL (1) IL263306B (es)
MX (2) MX2021009378A (es)
MY (1) MY191110A (es)
PE (1) PE20190811A1 (es)
PH (1) PH12018502507A1 (es)
RU (1) RU2714206C1 (es)
SA (2) SA518400547B1 (es)
SG (1) SG11201811470PA (es)
WO (1) WO2018004306A1 (es)
ZA (1) ZA201808431B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020002265A2 (pt) 2017-08-01 2020-07-28 Theravance Biopharma R&D Ip, Llc compostos pirazólicos e triazólicos bicíclicos como inibidores de jak quiinase
KR102577241B1 (ko) * 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체
MX2020006799A (es) 2017-12-28 2020-09-03 Daewoong Pharmaceutical Co Ltd Derivados de oxi-fluoropiperidina como inhibidor de cinasa.
KR102577242B1 (ko) * 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
CN108586341B (zh) * 2018-05-25 2020-05-08 天津商业大学 酰胺类化合物和其药用盐及其制备方法和药物用途
CA3109192A1 (en) * 2018-08-10 2020-02-13 Aclaris Therapeutics, Inc. Pyrrolopyrimidine itk inhibitors
EP3914348A1 (en) 2019-01-23 2021-12-01 Theravance Biopharma R&D IP, LLC Imidazo[1,5-a]pyridine, 1,2,4-triazolo[4,3-a]pyridine and imidazo[1,5-a]pyrazine as jak inhibitors
CA3109765A1 (en) * 2019-03-18 2020-09-24 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Btk inhibitor, pharmaceutically acceptable salt, polymorph and application thereof
CN110317176A (zh) * 2019-07-04 2019-10-11 沈阳药科大学 2-氨基嘧啶类化合物及其用途
CN114901659A (zh) 2019-11-26 2022-08-12 施万生物制药研发Ip有限责任公司 作为jak抑制剂的稠合嘧啶吡啶酮化合物
CN113214265B (zh) * 2020-01-21 2023-07-07 江苏先声药业有限公司 嘧啶并五元环类化合物
WO2021147953A1 (zh) * 2020-01-21 2021-07-29 江苏先声药业有限公司 嘧啶并五元环类衍生物及其应用
CN115023428A (zh) * 2020-01-21 2022-09-06 江苏先声药业有限公司 嘧啶并吡咯类化合物
CN111620878A (zh) * 2020-06-10 2020-09-04 中国药科大学 吡咯并嘧啶类衍生物作为蛋白激酶抑制剂及其应用
CN115916747A (zh) * 2020-07-01 2023-04-04 四川海思科制药有限公司 一种并环杂环衍生物及其在医药上的应用
WO2022062601A1 (zh) * 2020-09-22 2022-03-31 江苏先声药业有限公司 嘧啶并吡咯类化合物
CN114315838A (zh) * 2020-09-30 2022-04-12 江苏先声药业有限公司 嘧啶并吡咯类化合物
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
WO2023242597A1 (en) * 2022-06-16 2023-12-21 Amphista Therapeutics Limited Bifunctional molecules for targeted protein degradation
CN115368366A (zh) * 2022-08-02 2022-11-22 江苏省中医药研究院 嘧啶并吡唑类化合物及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
WO2003086371A2 (en) 2002-04-12 2003-10-23 Pfizer Japan Inc. Use of ep4 receptor ligands in the treatment of il-6 involved diseases
JP5071374B2 (ja) 2005-07-14 2012-11-14 アステラス製薬株式会社 ヘテロ環ヤヌスキナーゼ３阻害剤
CN103214484B (zh) 2005-12-13 2016-07-06 因塞特控股公司 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶
SI2526934T1 (sl) 2006-09-22 2016-04-29 Pharmacyclics Llc Inhibitorji Bruton tirozin kinaze
SG183036A1 (en) 2007-07-17 2012-08-30 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
WO2009026107A1 (en) * 2007-08-17 2009-02-26 Portola Pharmaceuticals, Inc. Protein kinase inhibitors
WO2009054941A1 (en) 2007-10-25 2009-04-30 Merck & Co., Inc. Therapeutic compounds
CA2723185A1 (en) 2008-04-22 2009-10-29 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
PE20091846A1 (es) * 2008-05-19 2009-12-16 Plexxikon Inc DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS
AU2009270856B2 (en) 2008-07-16 2013-07-25 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors
ES2659725T3 (es) 2009-05-05 2018-03-19 Dana-Farber Cancer Institute, Inc. Inhibidores de EGFR y procedimiento de tratamiento de trastornos
JP2013512282A (ja) 2009-12-01 2013-04-11 アボット・ラボラトリーズ 新規三環式化合物
AU2011269989B2 (en) 2010-06-23 2014-12-11 Hanmi Science Co., Ltd. Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
JP6110859B2 (ja) 2011-09-22 2017-04-05 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ヤヌスキナーゼ阻害剤としてのピラゾールカルボキサミド
AU2013204563B2 (en) * 2012-05-05 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
EP2964647A1 (en) * 2013-03-05 2016-01-13 F. Hoffmann-La Roche AG Inhibitors of bruton's tyrosine kinase
MX368491B (es) 2013-07-11 2019-10-04 Acea Biosciences Inc Derivados de pirimidina como inhibidores de cinasa.
AU2014323777C1 (en) 2013-09-18 2018-04-26 Beijing Hanmi Pharmaceutical Co., Ltd. Compound inhibiting activities of BTK and/or JAK3 kinases
SI3318565T1 (sl) 2013-12-05 2021-07-30 Pfizer Inc. Pirolo(2,3-D)pirimidinil, pirolo(2,3-B)pirazinil in pirolo(2,3-D)piridinil akrilamidi
CN105777756B (zh) * 2014-07-02 2019-03-01 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
CN105315285B (zh) * 2014-07-25 2017-12-08 上海海雁医药科技有限公司 2,4‑二取代7H‑吡咯并[2,3‑d]嘧啶衍生物、其制法与医药上的用途
KR101710127B1 (ko) 2014-08-29 2017-02-27 한화제약주식회사 야누스인산화효소 억제제로서의 치환된 N-(피롤리딘-3-일)-7H-피롤로[2,3-d]피리미딘-4-아민
CN105732637B (zh) * 2014-12-30 2020-04-21 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
US10913744B2 (en) 2015-02-13 2021-02-09 Dana-Farber Cancer Institute, Inc. LRRK2 inhibitors and methods of making and using the same

Also Published As

Publication number Publication date
SA521430937B1 (ar) 2022-12-25
US10961247B2 (en) 2021-03-30
EP3478687B1 (en) 2024-03-20
BR112018074621A2 (pt) 2019-03-06
JP7084961B2 (ja) 2022-06-15
KR102329162B1 (ko) 2021-11-22
CN113135920A (zh) 2021-07-20
ECSP18093777A (es) 2018-12-31
CN109311896A (zh) 2019-02-05
PE20190811A1 (es) 2019-06-13
NZ748746A (en) 2020-08-28
SA518400547B1 (ar) 2022-09-20
CL2018003511A1 (es) 2019-04-05
CA3025636A1 (en) 2018-01-04
BR112018074621B1 (pt) 2021-06-08
MY191110A (en) 2022-05-30
WO2018004306A1 (en) 2018-01-04
EP3478687A1 (en) 2019-05-08
RU2714206C1 (ru) 2020-02-13
EP3950691A1 (en) 2022-02-09
DOP2018000275A (es) 2018-10-31
KR20180003472A (ko) 2018-01-09
AU2017287762C1 (en) 2020-04-23
AU2017287762A1 (en) 2018-12-13
JP2019519579A (ja) 2019-07-11
MX2018016287A (es) 2019-05-20
CO2018013293A2 (es) 2018-12-14
JP2020143162A (ja) 2020-09-10
PH12018502507A1 (en) 2019-07-08
ZA201808431B (en) 2020-05-27
SG11201811470PA (en) 2019-01-30
EP3478687A4 (en) 2020-02-19
CN109311896B (zh) 2021-08-24
US20200317673A1 (en) 2020-10-08
CA3025636C (en) 2022-10-18
AU2017287762B2 (en) 2019-09-26
IL263306A (en) 2018-12-31
IL263306B (en) 2021-05-31

Similar Documents

Publication Publication Date Title
SA518400547B1 (ar) مشتقات بيرازولو بيريميدين كمثبط كيناز
TN2020000125A1 (en) Amino-fluoropiperidine derivative as kinase inhibitor
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
SA520412335B1 (ar) مشتقات أوكسي فلورو ببريدين كمثبط كيناز
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
MY196572A (en) Amino-Methyl Piperidine Derivative as Kinase Inhibitor
PH12019500480A1 (en) Pyridine compound
WO2015200481A8 (en) Mnk inhibitors and methods related thereto
MX2017000450A (es) Compuestos terapeuticos inhibidores.
MX2017013797A (es) Inhibidor de janus quinasa.
MX2018001992A (es) Compuestos triciclicos heterociclicos como inhibidores de fosfoinositol 3-quinasa.
MY193239A (en) Novel b-lactamase inhibitors
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
PH12019502046A1 (en) Pyrrolotriazine derivatives as kinase inhibitor
PH12017501955A1 (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease
MX2017007655A (es) Compuestos para tratar el cancer.